go-v.orgdoi

Renewable Feedstock Nanocarriers for Drug Delivery: Evidence Mapping and Translational Readiness

Renato Sonchini Gonçalves · Pharmaceutics · 2026

  • DOI 10.3390/pharmaceutics18040407
  • Publisher Multidisciplinary Digital Publishing Institute
  • Type review
  • Issued 2026

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Pharmaceutics · Multidisciplinary Digital Publishing Institute · review · 2026

Abstract

Sustainable nanotechnologies derived from renewable resources are increasingly being positioned at the interface of green chemistry, advanced drug delivery, and translational pharmaceutics. Over the past decade, lignocellulosic nanomaterials, chitin/chitosan platforms, polysaccharide-based nanogels and nano-enabled hydrogels, lignin- and polyphenol-derived nanostructures, and bio-based lipid nanocarriers have been engineered through progressively eco-efficient routes, including solvent-minimized self-assembly, nanoprecipitation, spray drying, hot-melt extrusion, and microfluidic-assisted fabrication.

This work provides a structured evidence map of nano-enabled drug delivery and therapeutic platforms derived from renewable biological resources. Specifically, we aim to (i) identify and classify nanoplatform classes and renewable feedstocks; (ii) summarize reported pharmaceutical critical quality attributes (CQAs) and performance and safety endpoints; and (iii) appraise how "renewability" and "green" claims are evidenced (feedstock origin vs. process sustainability) and how frequently translational readiness factors (scalability, quality control, regulatory alignment) are addressed.

We critically compare renewable and conventional nanomaterial platforms across key translational dimensions, including carbon footprint, batch consistency, biodegradability, functional tunability, safety/persistence, and scale-up maturity. Finally, we delineate a practical translational pathway-from biomass sourcing and fractionation to nanoformulation, characterization/stability, and GMP scale-up-highlighting cross-cutting enablers such as lifecycle assessment, EHS/toxicology risk assessment, quality-by-design, and regulatory alignment.

Collectively, the evidence supports renewable nanomaterials as viable, scalable candidates for next-generation therapeutics, provided that variability control, standardized characterization, and safety-by-design principles are embedded early in development.

Open the resolved locator · 10.3390/pharmaceutics18040407

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 04:44 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.3390/pharmaceutics18040407
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.